Novo's obesity business and Chinese challenges will be examined closely, says analyst

A new insulin supply model in China is expected to affect sales next year, and this challenge combined with Novo Nordisk's sales figures for obesity drugs will be ABG Sundal Collier's main focus when the Danish pharmaceutical company releases its financial report tomorrow.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Novo Nordisk's obesity business and the insulin sales prospects in China could take center stage when the Danish pharmaceutical company releases its quarterly report Wednesday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading